With nearly 20 years’ experience advising companies and banks on some of their most complex and sophisticated transactions, Wesley C. Holmes built a reputation as a leading healthcare lawyer not only in Boston, but in the U.S. and globally — one who invests himself not only in the matter at hand, but in the long-term success of the client.

Holmes has built that reputation by helping his clients at Latham & Watkins achieve their most ambitious objectives on broad range of transactions, including public securities offerings, high-yield debt offerings, M&A finance, and private and venture offerings.

In fact, just within the past year, Holmes has advised on more than 30 matters valued at more than $14 billion.

Holmes’s accomplishments include leading a team that represented P3 Health Partners, a patient-centered and physician-led population health management company, in its completed business combination with publicly traded Foresight Acquisition Corp.

Holmes also led the team that represented Altaris Capital in the sale of its portfolio company BK Medical, a designer and manufacturer of medical devices, to GE Healthcare, a subsidiary of General Electric.

That acquisition — reportedly GE’s largest under Larry Culp, who has focused heavily on paying down GE’s debt since taking over as CEO in 2018 — will enable the company to expand its ultrasound business from diagnostics to surgical imaging.

Holmes represented Rapid Micro Biosystems, an innovative Massachusetts-based life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, in its initial public offering of more than 9 million shares of Class A Common Stock listed on Nasdaq.

In addition, Holmes led the team that represented Sight Sciences, Inc. in its $240 million IPO on Nasdaq. The growth-stage medical device company focuses on the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases.